Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Lucky888 who wrote (24020)	3/25/1999 11:18:00 AM
From: tsunami	Read Replies (1) \| Respond to of 122087

anyone get burned with ITVU run up to 49 yet? shorted @ 47 3/4. free money if you can handle the squeeze, will box north of 60. good luck

To: Lucky888 who wrote (24020)	3/25/1999 11:26:00 AM
From: Anthony@Pacific	Respond to of 122087

DRMD<--------------FDA DENIES ITS REPLACEMENT of Premerin!!! Drexel deal from 1986.. The FDA didn't find Cenestin equivalent to Premarin and limited the approval to treating menopausal symptoms such as hot flashes. Unlike Premarin, Cenestin won't be approved for long- term use, including the treatment of osteoporosis, and pharmacists won't be able to replace Premarin with Cenestin. Still, Cenestin is likely to be cheaper than Premarin. As such, the drug will compete with other therapies that are also cheaper than -- and not equivalent to -- Premarin, analysts said. Duramed Chairman Thomas Arington said the company is working on a marketing plan for launching Cenestin within 90 days as ''the first step in Duramed's long-term program to build a family of hormone products.''